Blueprint Medicines Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Blueprint Medicines (BPMC) Tops Q1 EPS by 6c, Revenues Beat
May 6, 2020 7:19 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($2.11), $0.06 better than the analyst estimate of ($2.17). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $5.44 million.
"Our progress in recent months is a testament to the agility of the Blueprint... More
